LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group

Marinde J. G. Bond, Cornelis J.A. Punt, Mathijs P. Hendriks et al.|Annals of Oncology|2022

Cited by 5